Azitra, Inc. to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Core Insights - Azitra, Inc. is a clinical stage biopharmaceutical company focused on innovative therapies for precision dermatology [4] - The company will present at the H.C. Wainwright 27th Annual Global Investment Conference from September 8-10, 2025 [3] - Recent updates include promising safety results from the Phase 1b clinical trial of the ATR-12 program for Netherton syndrome and the initiation of the Phase 1/2 trial for the ATR-04 program targeting EGFR inhibitor-associated dermal toxicity [2][4] Company Overview - Azitra's lead program, ATR-12, targets Netherton syndrome, a rare skin disease with no approved treatments, and is currently in a Phase 1b clinical trial [4] - The ATR-04 program addresses EGFR inhibitor-associated rash, which affects approximately 150,000 people in the U.S., and has received Fast Track designation from the FDA [4] - The company utilizes a proprietary platform of engineered proteins and a microbial library of around 1,500 bacterial strains, enhanced by AI and machine learning for drug discovery [4] Presentation Details - The virtual presentation by Travis Whitfill, Cofounder and COO, is scheduled for 7:00 AM ET on September 8, 2025 [3] - During the conference, one-on-one meetings will be held with registered investors and potential partners to discuss the company's business and clinical development strategy [3]